Abivax CEO Highlights Pipeline Assets, Including Lead HIV Drug
Abivax CEO Dr. Hartmut Ehrlich talks to Scrip senior editor Lucie Ellis about the progress and next development steps for its lead clinical-stage molecule against HIV virus.
You may also be interested in...
Hepatitis C is effectively cured. Could this success be replicated in another serious chronic viral condition ‒ HIV? Abivax, which last year abandoned its hepatitis B lead program, has bounced back with data suggesting a 'functional cure' for HIV is more than just a pipe dream.
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.